Leupaxin (LPXN)

Leupaxin (LPXN) is an adapter protein belonging to the paxillin family, characterized by four N-terminal leucine-rich LD motifs and four C-terminal LIM domains, and is predominantly expressed in hematopoietic cells, osteoclasts, smooth muscle, and some tumor cells[2][4][5]. It is involved in mediating protein-protein interactions at focal adhesions to regulate cytoskeletal dynamics, cell adhesion, and migration. Leupaxin acts as a transcriptional coactivator for the androgen receptor and serum response factor, influencing gene expression, and serves as a negative regulator of B-cell antigen receptor signaling[2][3][5]. Mechanistically, leupaxin interacts with kinases such as PYK2, FAK, and ERK, influencing phosphorylation cascades relevant for cytoskeletal remodeling and migration, especially in prostate cancer cells[1]. Overexpression of leupaxin is linked to increased invasiveness in prostate cancer and altered smooth muscle or osteoclast function, making it of interest as a biological marker and potential target for cancer and bone disease research, though it is not the direct subject of current targeted drug therapies[1][3][5]. No current evidence indicates leupaxin (LPXN) is a misspelling, a non-existent target, or should be classified as incorrect; however, no clinically approved therapies are known to target this protein directly.

Other names

LDLPLDPLleupaxinLPXN

No direct small-molecule or biologic mechanisms established; functional activity is through modulation of protein-protein interactions and signaling complexes.